DMD Celsis microsomes equal better data

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Cho, A. K.
Right arrow Articles by Jenden, D. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Cho, A. K.
Right arrow Articles by Jenden, D. J.

Stereochemical differences in the metabolism of 3,4- methylenedioxymethamphetamine in vivo and in vitro: a pharmacokinetic analysis

AK Cho, M Hiramatsu, EW Distefano, AS Chang and DJ Jenden

Department of Pharmacology, School of Medicine, University of California, Los Angeles 90024-1735.

The in vivo N-demethylation of (+) and (-)3,4- methylenedioxymethamphetamine (MDMA) to 3,4-methylenedioxyamphetamine (MDA) was determined and the pharmacokinetic relationship between the two compounds calculated. The levels of MDA formed after iv administration of (+)MDMA to male rats were about 3 times greater than those for (-)MDMA, although the plasma levels of the parent drugs were comparable. Plasma MDA concentrations were lower in phenobarbital- pretreated rats, but SKF 525-A pretreatment, at the dose used, had minimal effects. In liver microsome experiments conducted with microM concentrations of (+)MDMA, 3,4-dihydroxymethamphetamine (N-methyl-alpha- methyldopamine) was shown to be the major metabolite. MDA was also formed in vitro, but the enantioselectivity was the opposite of that found in vivo, pointing out the difficulties in extrapolation of in vitro observations to in vivo disposition. The high levels of MDA observed after administration of (+)MDMA to intact animals suggest that this active metabolite could be important in the overall effects of (+)MDMA.

Volume 18, Issue 5, pp. 686-691, 09/01/1990
Copyright © 1990 by American Society for Pharmacology and Experimental Therapeutics




This article has been cited by other articles:


Home page
 J PsychopharmacolHome page
N. Easton and C. A. Marsden
Ecstasy: Are animal data consistent between species and can they translate to humans?
J Psychopharmacol, March 1, 2006; 20(2): 194 - 210.
[Abstract] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
E. Meririnne, S. Ellermaa, A. Kankaanpaa, A. Bardy, and T. Seppala
Pharmacokinetics and Tissue Distribution of the Stereoisomers of 4-Methylaminorex in the Rat
J. Pharmacol. Exp. Ther., June 1, 2004; 309(3): 1198 - 1205.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
J. K. Fallon, A. T. Kicman, J. A. Henry, P. J. Milligan, D. A. Cowan, and A. J. Hutt
Stereospecific Analysis and Enantiomeric Disposition of 3,4-Methylenedioxymethamphetamine (Ecstasy) in Humans
Clin. Chem., July 1, 1999; 45(7): 1058 - 1069.
[Abstract] [Full Text] [PDF]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 1990 by the American Society for Pharmacology and Experimental Therapeutics.